Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NuVasive, Inc.
  6. News
  7. Summary
    NUVA   US6707041058

NUVASIVE, INC.

(NUVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NuVasive : J.P. Morgan 40th Annual Healthcare Conference

01/10/2022 | 07:08pm EDT
share with twitter
share with LinkedIn
share with facebook
Event Details
J.P. Morgan 40th Annual Healthcare Conference
Webcast Presentation
Event Details
Title J.P. Morgan 40th Annual Healthcare Conference
Date and Time Wednesday, 01/12/22 at 3:00 PM EST

Disclaimer

NuVasive Inc. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 00:07:01 UTC.


© Publicnow 2022
All news about NUVASIVE, INC.
05/12NUVASIVE INC : Change in Directors or Principal Officers, Submission of Matters to a Vote ..
AQ
05/12NuVasive, Inc. Announces Management Changes
CI
05/06Morgan Stanley Adjusts NuVasive Price Target to $62 From $60, Maintains Equal Weight Ra..
MT
05/05RBC Capital Adjusts NuVasive's Price Target to $63 From $60, Maintains Outperform Ratin..
MT
05/05Wells Fargo Adjusts NuVasive's Price Target to $62 From $58, Reiterates Overweight Rati..
MT
05/05Needham Raises NuVasive's Price Target to $67 From $64, Reiterates Buy Rating
MT
05/04NUVASIVE : Q1 Earnings Snapshot
AQ
05/04NuVasive Logs Upbeat Q1 Results, Lifts FY22 Guidance
MT
05/04Earnings Flash (NUVA) NUVASIVE Reports Q1 EPS $0.54, vs. Street Est of $0.39
MT
05/04Earnings Flash (NUVA) NUVASIVE Posts Q1 Revenue $290.8M, vs. Street Est of $277.6M
MT
More news
Analyst Recommendations on NUVASIVE, INC.
More recommendations
Financials (USD)
Sales 2022 1 222 M - -
Net income 2022 79,1 M - -
Net Debt 2022 546 M - -
P/E ratio 2022 38,6x
Yield 2022 -
Capitalization 2 760 M 2 760 M -
EV / Sales 2022 2,71x
EV / Sales 2023 2,49x
Nbr of Employees 2 900
Free-Float 88,3%
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | NUVA | US6707041058 | MarketScreener
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 53,03 $
Average target price 64,07 $
Spread / Average Target 20,8%
EPS Revisions
Managers and Directors
J. Christopher Barry Chief Executive Officer & Director
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Daniel J. Wolterman Chairman
Kyle Malone Vice President-Scientific Affairs
Aviva McPherron Senior Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NUVASIVE, INC.1.05%2 760
ABBOTT LABORATORIES-19.54%196 876
MEDTRONIC PLC-0.89%137 843
BECTON, DICKINSON AND COMPANY2.66%71 591
BAXTER INTERNATIONAL INC.-14.69%36 556
HOYA CORPORATION-26.33%36 134